This company has been marked as potentially delisted and may not be actively trading. Cardiff Oncology (TROV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock TROV vs. TARA, CGEN, NMRA, CHRS, CCCC, ALEC, ENTX, ZURA, SNTI, and HLVXShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Protara Therapeutics (TARA), Compugen (CGEN), Neumora Therapeutics (NMRA), Coherus BioSciences (CHRS), C4 Therapeutics (CCCC), Alector (ALEC), Entera Bio (ENTX), Zura Bio (ZURA), Senti Biosciences (SNTI), and HilleVax (HLVX). These companies are all part of the "medical" sector. Cardiff Oncology vs. Protara Therapeutics Compugen Neumora Therapeutics Coherus BioSciences C4 Therapeutics Alector Entera Bio Zura Bio Senti Biosciences HilleVax Cardiff Oncology (NASDAQ:TROV) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation. Do insiders and institutionals hold more shares of TROV or TARA? 10.0% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 0.6% of Cardiff Oncology shares are owned by company insiders. Comparatively, 12.5% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, TROV or TARA? Cardiff Oncology has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Do analysts recommend TROV or TARA? Protara Therapeutics has a consensus target price of $20.40, suggesting a potential upside of 482.86%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor TROV or TARA? In the previous week, Protara Therapeutics had 8 more articles in the media than Cardiff Oncology. MarketBeat recorded 9 mentions for Protara Therapeutics and 1 mentions for Cardiff Oncology. Protara Therapeutics' average media sentiment score of 0.44 beat Cardiff Oncology's score of 0.00 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protara Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TROV or TARA more profitable? Protara Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. Protara Therapeutics' return on equity of -55.96% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-3,688.31% -202.00% -122.92% Protara Therapeutics N/A -55.96%-49.06% Which has higher valuation and earnings, TROV or TARA? Cardiff Oncology has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$250K120.68-$16.41M-$2.80-0.98Protara TherapeuticsN/AN/A-$40.42M-$2.40-1.46 Does the MarketBeat Community believe in TROV or TARA? Cardiff Oncology received 361 more outperform votes than Protara Therapeutics when rated by MarketBeat users. Likewise, 73.09% of users gave Cardiff Oncology an outperform vote while only 69.49% of users gave Protara Therapeutics an outperform vote. CompanyUnderperformOutperformCardiff OncologyOutperform Votes40273.09% Underperform Votes14826.91% Protara TherapeuticsOutperform Votes4169.49% Underperform Votes1830.51% SummaryProtara Therapeutics beats Cardiff Oncology on 12 of the 17 factors compared between the two stocks. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TROV vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.17M$3.00B$5.56B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.9030.4222.5718.48Price / Sales120.68498.92395.64103.60Price / CashN/A168.6838.1834.62Price / Book2.913.206.774.25Net Income-$16.41M-$72.35M$3.22B$248.23M Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TROVCardiff OncologyN/A$2.74-1.4%N/A-36.2%$30.17M$250,000.00-0.90N/ATARAProtara Therapeutics2.2484 of 5 stars$3.52-18.5%$20.40+479.5%+17.4%$129.42MN/A-1.2530Analyst ForecastNews CoverageHigh Trading VolumeCGENCompugen2.0649 of 5 stars$1.44-2.7%$4.00+177.8%-17.1%$128.50M$27.86M72.0070Positive NewsNMRANeumora Therapeutics3.139 of 5 stars$0.76+0.7%$9.29+1,117.6%-91.4%$123.35MN/A-0.41108CHRSCoherus BioSciences3.5289 of 5 stars$1.03flat$5.26+410.9%-47.4%$119.37M$266.96M-12.88330Upcoming EarningsAnalyst ForecastNews CoverageCCCCC4 Therapeutics2.4306 of 5 stars$1.62+5.2%$12.50+671.6%-74.0%$115.03M$35.58M-0.95150Upcoming EarningsNews CoveragePositive NewsALECAlector3.657 of 5 stars$1.16+1.8%$3.50+201.7%-76.4%$114.94M$100.56M-0.68270Upcoming EarningsNews CoveragePositive NewsENTXEntera Bio2.1603 of 5 stars$2.28-5.0%$10.00+338.6%+10.7%$103.56M$181,000.00-8.7720Gap DownZURAZura Bio3.1003 of 5 stars$1.41+2.9%$14.67+940.2%-63.9%$96.41MN/A-2.663Upcoming EarningsShort Interest ↓News CoverageSNTISenti Biosciences2.8608 of 5 stars$3.64-27.2%$10.00+174.7%-7.8%$94.66M$2.56M-0.234Upcoming EarningsNews CoverageHigh Trading VolumeHLVXHilleVax2.7715 of 5 stars$1.88+1.6%$3.00+59.6%-85.3%$94.27MN/A-0.6120Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies TARA Competitors CGEN Competitors NMRA Competitors CHRS Competitors CCCC Competitors ALEC Competitors ENTX Competitors ZURA Competitors SNTI Competitors HLVX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TROV) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TROV Stock Free TROV Stock Alerts